Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Informa CompLaw Antitrust West Coast Conference 2026
Speaking Engagement
Antitrust
2026 FDLI Annual Conference
Speaking Engagement
Intellectual Property
Let's Talk "About". . . That Bird?
Axinn Viewpoints
Intellectual Property
What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions
Axinn Viewpoints
Antitrust
Seven Axinn Attorneys Named to 2025 Capital Pro Bono Honor Roll
Pro Bono
Antitrust
Axinn Advises Thermo Fisher Scientific on $1.075 Billion Sale of its Microbiology Business to Astorg
Deals & Cases
Antitrust
Axinn Appoints Rachael Philbin as Chief Innovation Officer
News
Teva v. Lilly -- Clarifies Written Description of Method Claims Involving A Genus
Axinn Viewpoints
Intellectual Property
What’s Up? Competition Enforcement Updates From Italy and Portugal
Podcast
Antitrust
